

## Glycan Recognition

# Exploring lectin–glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses

Luís Cláudio Nascimento da Silva<sup>1,2,3,1</sup>,  
Juliana Silva Pereira Mendonça<sup>2</sup>, Wesley Felix de Oliveira<sup>4</sup>,  
Karla Lílian Rodrigues Batista<sup>3</sup>, Adrielle Zagnignan<sup>3</sup>,  
Isabelle Freire Tabosa Viana<sup>5</sup>, and Maria Tereza dos Santos Correia<sup>4</sup>

<sup>2</sup>Programa de Pós-graduação em Biologia Microbiana, Laboratório de Patogenicidade Bacteriana, Universidade CEUMA, São Luís 65075-120, Brazil, <sup>3</sup>Programa de Pós-graduação em Biodiversidade e Biotecnologia da Amazônia Legal, Laboratório de Patogenicidade Bacteriana, Universidade CEUMA, São Luís 65075-120, Brazil, <sup>4</sup>Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Recife 50.670-901, Brazil, and <sup>5</sup>Departamento de Virologia, Instituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, 50670-420, Brazil

<sup>1</sup>To whom correspondence should be addressed: Tel: +55-98-3214-4127; Fax: +55 98 3235-3265; e-mail: luisclaudionsilva@yahoo.com.br; luiscln.silva@ceuma.br

Received 9 May 2020; Revised 30 August 2020; Editorial Decision 26 September 2020; Accepted 26 September 2020

### Abstract

The emergence of a new human coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has imposed great pressure on the health system worldwide. The presence of glycoproteins on the viral envelope opens a wide range of possibilities for the application of lectins to address some urgent problems involved in this pandemic. In this work, we discuss the potential contributions of lectins from nonmammalian sources in the development of several fields associated with viral infections, most notably COVID-19. We review the literature on the use of nonmammalian lectins as a therapeutic approach against members of the *Coronaviridae* family, including recent advances in strategies of protein engineering to improve their efficacy. The applications of lectins as adjuvants for antiviral vaccines are also discussed. Finally, we present some emerging strategies employing lectins for the development of biosensors, microarrays, immunoassays and tools for purification of viruses from whole blood. Altogether, the data compiled in this review highlight the importance of structural studies aiming to improve our knowledge about the basis of glycan recognition by lectins and its repercussions in several fields, providing potential solutions for complex aspects that are emerging from different health challenges.

**Key words:** antiviral therapy, biosensors/blood purification, immunization, viral glycoproteins

## Introduction

The year of 2020 has been marked by the global dissemination of a new type of severe acute respiratory syndrome, defined as COVID-19 (Rothan and Byrareddy 2020; Yi et al. 2020). The novel type of human coronavirus provoking the Severe acute respiratory syndrome (SARS-CoV-2 or 2019-nCoV) was first reported in Wuhan (China) in December 2019. This virus has genetic similarity to other types of *Betacoronavirus* involved in the recent outbreaks in Asia: (i) SARS-CoV, the etiologic agent of an outbreak of severe acute respiratory syndrome in China in 2003; (ii) MERS-CoV, the virus identified as the cause of a severe respiratory syndrome in Middle East in 2012 (Zhang and Holmes 2020). However, SARS-CoV-2 has higher dissemination rates than MERS-CoV and SARS-CoV, imposing serious challenges to health systems worldwide (Requia et al. 2020; Sun et al. 2020b).

The initial symptoms of COVID-19 disease are similar to the common cold. However, this infection can progress to severe respiratory failure with impaired and deleterious immunological responses (Li et al. 2020a; Sun et al. 2020a; Xu et al. 2020). This state is characterized by increased ratios of monocytes and neutrophils and exacerbated release of inflammatory mediators (especially IL-6) that may contribute to dysfunction of multiple organs (Qin et al. 2020; Xu et al. 2020). Despite the occurrence of other coronavirus outbreaks, there is still no specific therapy or vaccine for COVID-19 (Alanagreh et al. 2020; Pastick et al. 2020).

Other important concern is the urgent need for simple and fast devices for viral detection in clinical and environmental samples (Liang et al. 2020; Qiu et al. 2020). Particularly, the early detection of SARS-CoV-2 in asymptomatic and/or presymptomatic individuals is important to break the chain of transmission (Arons et al. 2020; Furukawa et al. 2020). The extracorporeal removal of SARS-CoV-2 from blood by plasmapheresis is also important for the implementation of alternative therapies (Turgutkaya et al. 2020). This complex panorama has imposed a race against time across different fields of knowledge (biomedical science, biotechnology, drug development, molecular analysis, etc.) to offer the maximum number of solutions to these and other issues raised by this pandemic (Venkatakrishnan et al. 2020).

SARS-CoV-2 has a lipoprotein envelope surrounding the infectious virion particles which is derived from the host cell during the budding (Bianchi et al. 2020; Sternberg and Naujokat 2020). The viral envelope has two layers of lipids whose composition depends on the type of membrane from which this structure is derived (Cosset and Lavillette 2011). The proteins are interspersed in the lipid layers and some of them are glycosylated by host enzymes (Carbaugh and Lazear 2020; Cipollo and Parsons 2020). Like other enveloped viruses, the envelope glycoproteins of SARS-CoV-2 are involved in the process of viral adhesion and entry (Sternberg and Naujokat 2020; Verma et al. 2020).

For instance, the envelope of SARS-CoV-2 exhibits glycoproteins such as spike (S-protein) and membrane (M-protein) proteins (Ahmed et al. 2020; Shajahan et al. 2020) (Supplementary Figure S1A). These structural proteins (specially S-protein) exert central roles in viral pathogenesis and are pointed as important targets for neutralizing antibodies, vaccine and drug design (Ahmed et al. 2020; Bagdonaite and Wandall 2018). Besides, nonstructural proteins are also found in glycosylated forms, such as the 3a protein, which plays an essential role in SARS-CoV-2 virulence (Fung and Liu 2018; Issa et al. 2020). The presence of glycoproteins in the viral envelope opens a wide range of possibilities for application of carbohydrate binding agent, such as lectins, to address some urgent problems involved in this pandemic situation.

Lectins comprise a large class of proteins sharing the ability to recognize specific types of carbohydrates residues (Coelho et al. 2017). They are ubiquitously distributed in the organisms where they participate in sugar storage, immune defense systems and other physiological processes (Ribeiro et al. 2014; Brown et al. 2018; Prado Acosta and Lepenies 2019). Moreover, lectins from pathogenic agents (including viruses, bacteria and fungi) are involved in their virulence mechanisms through binding to glycans present on the host cell surfaces (Patra et al. 2014; Van Breedam et al. 2014; Landi et al. 2019).

The recognition of glycans allows the use of lectins for several biotechnological applications (Swanson et al. 2015; de Oliveira Figueiroa et al. 2017; Hamorsky et al. 2019). Importantly, these agglutinins are pointed as broad-spectrum inhibitors of viral invasion since they could target sugar moieties in the surface proteins and block the adhesion to the host cells (Wang et al. 2015; Mitchell et al. 2017; Gondim et al. 2019). The interaction with glycoproteins also allows the use of lectins in the development of devices for identification and characterization of glycoproteins in the viral envelope or alterations in the host glycoproteins during viral infection (Andrade et al. 2011; Koch et al. 2018; Simao et al. 2020).

Herein, we discuss the potential contributions of nonmammalian lectins in the development of different fields of viral infections research, using COVID-19 disease as background. Given the recent emergence of the SARS-CoV-2, we review some lessons acquired from previous studies on closely related coronaviruses (SARS-CoV, MERS-CoV) and other enveloped viruses. In this regard, the possible applications of lectins include: (i) design of leading molecules for antiviral therapy; (ii) development of adjuvant compounds for immunization; (iii) establishment of approaches to characterize glycosylation of viruses or infected host protein structures and (iv) development of devices for viral detection and purification. We also discuss the challenges and limitations for each target application.

## Overview of glycosylation of viral proteins

Glycosylation is the most common type of posttranslational modification (PTM), which significantly regulates the structure (folding and stability) and functions of proteins (Cipollo and Parsons 2020; Ohyama et al. 2020). Glycans are involved in viral adhesion and epitope shielding from antibody recognition, therefore glycosylation sites may be under selective pressure (Vankadari and Wilce 2020; Watanabe et al. 2019). The synthesis, folding and glycosylation (as other PTMs) of viral proteins depend on host organelles (ribosomes, endoplasmic reticulum and Golgi apparatus) and enzymes (glyco-transferases and glycosidases) (Carbaugh and Lazear 2020; Cipollo and Parsons 2020).

The current experimental data regarding the glycosylation of viral proteins are dependent on the carbohydrate processing enzymes available in the biological systems used to propagate the viral strain. In this sense, our knowledge about the natural pattern of viral glycosylation is very limited (Bagdonaite et al. 2018; Cipollo and Parsons 2020). It is also important to consider that viral proteins may follow different pathways than those observed from host glycoproteins (Watanabe et al. 2019).

The covalent addition of glycans in viral proteins occurs mainly through two pathways: (i) N-glycosylation, when the glycan is connected to asparagine (Asn) residues and (ii) O-glycosylation, when the modification is performed in oxygen atoms of serine (Ser) and threonine (Thr) residues [sometimes tyrosine (Tyr) residues are used]

(Watanabe et al. 2019). The mucin-type O-glycosylation, also known as N-acetylgalactosamine (GalNAc)-type, is the most commonly observed in viral proteins (Hargett and Renfrow 2019; Chen et al. 2020).

The process of N-glycosylation of viral proteins in mammalian cells starts in parallel with their synthesis. In the cytoplasmic side of endoplasmic reticulum (ER), the glycan precursor is synthesized containing three glucose (Glc), nine mannose (Man) and two N-acetylglucosamine (GlcNAc) (Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub>) glycosylation sites (Hargett and Renfrow 2019). This precursor is transferred to the ER lumen and modified by the addition of monosaccharides (Fung and Liu 2018).

The mature glycan structure is then added, by an oligosaccharyltransferase, to the Asn residue of an Asn-X-Ser/Thr motif (“X” in any amino acid, except proline) in the nascent protein chain (Carbaugh and Lazear 2020). Following, other enzymes from the ER and Golgi apparatus (glucosidases, mannosidases, galactosyl-, fucosyl- and sialyl-transferases) modify the structure, which results in the diversification of glycan molecules that are allocated in the classes: oligomannose, hybrid and complex-type N-glycan structures (Supplementary Figure S1B) (Fung and Liu 2018; Watanabe et al. 2019).

The mucin-type O-glycosylation can be considered more complex than N-glycosylation. The first takes place in the Golgi apparatus, where a group of GalNAc-transferases mediates the insertion of GalNAc monosaccharide to the appropriated amino acids residues (Ser, Thr or Tyr) (Hargett and Renfrow 2019; Cipollo and Parsons 2020). Next, glycosyltransferases can process the O-linked glycan, generating the eight types of cores (cores 1–8) (as shown in Supplementary Figure S1C). The core types 1–4 are the most common in mammalian systems. During the passage through the Golgi apparatus, these structures are further altered, which leads to the diversification of mucin-type O-linked glycans (Hargett and Renfrow 2019; Watanabe et al. 2019).

### Glycosylation profile of the spike protein from SARS-CoV-2

Glycoproteins of SARS-CoV-2 are involved in cell adhesion and invasion, morphogenesis and modulation immune response processes (Fung and Liu 2018; Issa et al. 2020; Walls et al. 2020). Although other SARS-CoV-2 proteins have predictable glycosylation sites (such as M-protein, E-protein), the majority of experimental data are currently available is based on the S-protein (Supplementary Figure S1D) (Andersen et al. 2020; Watanabe et al. 2020). This is a trimeric protein that mediates the viral adhesion through binding to the human angiotensin-converting enzyme 2 (hACE2) and also interacts with the host immune defense (Ou et al. 2020; Vankadari and Wilce 2020; Walls et al. 2020).

The S-protein from SARS-CoV-2 has two functional subunits (S1 and S2) with 22 and 3 potential sites for N-glycosylation and O-glycosylation, respectively (Andersen et al. 2020; Watanabe et al. 2020). Despite the similarity with SARS-CoV spike (approximately 87.2%), some differences in the glycosylation sites repertoire and known epitopes have been reported for SARS-CoV-2 spike (Kumar et al. 2020; Vashi et al. 2020). For instance, it exhibits an unusual cleavage site for the furin protease between the S1/S2 subunits, which is not observed in SARS-CoV. The N-linked glycans were recently mapped by cryoelectron microscopy in 16 amino acid residues of the S-protein expressed in HEK293F cells (from human embryonic kidney) (Walls et al. 2020).

More details on N-glycosylation profiles of the 22 sites were unraveled using recombinant proteins expressed in HEK293F cells. The oligomannose-type glycans were predominant in two sites (N234 and N709). Complex-type glycans were predominantly exhibited in 14 amino acid residues (N17, N74, N149, N165, N282, N331, N343, N616, N657, N1098, N1134, N1158, N1173 and N1194), while six sites showed a mixture of oligomannose- and complex-type glycans (N61, N122, N603, N717, N801 and N1074). The most common configuration of oligomannose-type glycans was Man<sub>5</sub>GlcNAc<sub>2</sub>. Afucosylated and fucosylated hybrid-type glycans were detected in at least nine sites. The authors highlighted that the glycosylation profile of the SARS-CoV-2 S-protein was different from those observed for host glycoproteins or for other enveloped viruses (Watanabe et al. 2020).

Other experimental study evaluated the N-glycosylation and O-glycosylation of spike protein subunits, also using the HEK293-based expression system. The authors have solved the structures of N-linked glycans in 17 predicted sites and reported the presence of 3 classes of N-glycans. Importantly, this study revealed O-glycosylation modifications on two residues (Thr323 and Ser325) present in the receptor-binding domain (RBD) of the S1 subunit (Shajahan et al. 2020). Recently, the characterization of the glycosylation profile of the S-protein expressed in BTI-Tn-5B1-4 insect cells was reported showing the presence of high-mannose N-glycans in all 22 predicted sites. Interestingly, these glycans cover almost all of the RBD area (Zhou et al. 2020).

### Lectins can target envelope glycoproteins and inhibit the adhesion of coronavirus to host cell receptors

As previously mentioned, the S-protein of SARS-CoV-2 has a crucial role in viral adhesion by binding to hACE2. Therefore, the disruption of this interaction is considered an attractive target for antiviral therapy (Battie et al. 2020; Ou et al. 2020). Some nonmammalian-derived lectins (from plants and bacteria) are pointed as alternative antiviral agents against enveloped viruses due to their ability to recognize the glycans present in the structural proteins and to impair the initial steps of viral pathogenesis (Mitchell et al. 2017) (Supplementary Figure S2A and B).

Given the recent emergence of SARS-CoV-2, only the lectin isolated from *Lablab purpureus* [Flt3 receptor-interacting lectin (FRIL)] has been reported so far as an antiviral agent against this virus. FRIL is a glucose/mannose lectin also known as DLL-I. This protein completely inhibited the cytopathic effect of SARS-CoV-2 (strain hCoV-19/Taiwan/NTU04/2020) toward Vero cells at concentrations higher or equal than 6.25 µg/mL. The PRNT50 (50% plaque reduction neutralization test) and microneutralization EC50 (half-maximal effective concentration) values for FRIL against hCoV-19/Taiwan/NTU04/2020 were 0.71 and 0.80 µg/mL, respectively. This action was correlated with the ability of FRIL to bind to SARS-CoV-2 S-protein harboring complex-type N-glycans [as shown by enzyme-linked immunosorbent assay (ELISA)-lectin assay]. The authors also showed that FRIL treatment impairs the synthesis of SARS-CoV-2 N-protein and SARS-CoV-2 S-protein. Furthermore, FRIL has in vitro and in vivo action against influenza virus (Liu et al. 2020b).

Besides these insights given by the anti-SARS-CoV-2 action of FRIL, other important lessons can be learned from other SARS-CoV and related viruses (as summarized in Table I). For instance, a study evaluated the in vitro antiviral activity of 33 plant lectins

toward coronaviruses (SARS-CoV and feline infectious peritonitis virus). Mannose-binding agglutinins showed the highest anti-SARS-CoV effects. Among the studied lectins, the higher selective indexes (SIs) were found for the ones isolated from *Allium porrum* (APA; SI > 222.2), *Morus nigra* (Morniga M II; SI > 62.5) and *Epipactis helleborine* (EHA; SI > 55.5). *Urtica dioica* (UDA) and *Nicotiana tabacum* agglutinins (NICTABA), both specific for GlcNAc, also showed promising activity (SI > 76.9 and >58.8, respectively) (Keyaerts et al. 2007). NICTABA and UDA have also shown inhibitory activity against other enveloped viruses including influenza A/B, dengue virus type 2 (DENV-2), herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and human immunodeficiency viruses (HIV-1/2) (Gordts et al. 2015).

The in vivo activity of UDA was reported in murine models of lethal SARS-CoV (Day et al. 2009; Kumaki et al. 2011). Initially, the potential effects of UDA was associated to the reduction of IL-6 levels in the lungs (Day et al. 2009). Following, the UDA mechanism of action was further detailed and revealed that UDA-treated mice exhibited fewer pathologic alterations in the lung and higher survival indexes, when compared to the placebo-treated group. Further, the authors showed that this lectin targets the viral invasion by binding to the S-protein since the UDA protective effects were impaired in the presence of GlcNAc (Kumaki et al. 2011).

Other plant lectins have been shown to exhibit inhibitory action toward other coronaviruses. Examples include the following mannose-binding lectins: concanavalin A (Con A), *Hippeastrum hybrid* agglutinin (HHA), *Galanthus nivalis* agglutinin (GNA or GNL) (Greig and Bouillant 1977; Nguyen et al. 1987; van der Meer, de Haan, Schuurman, Haijema, Peumans et al. 2007; Hsieh et al. 2010). One of these studies highlighted the importance of glycosylation in the sensibility of two types of coronaviruses (mouse hepatitis virus and feline infectious peritonitis virus) toward GNA, UDA and HHA. In this case, the inhibition of host mannosidases resulted in the improved antiviral activity of the mannose- and GlcNAc-binding lectins (van der Meer, de Haan, Schuurman, Haijema, Verheije et al. 2007). GNA was also recently reported as an inhibitor of cell entry mechanism of influenza A H3N2 (Thompson et al. 2020).

Nonplant-derived agglutinins are also pointed as promising agents against coronaviruses, e.g. the mannose-binding-lectins cyanovirin-N (from cyanobacterium *Nostoc ellipsosporum*) and griffithsin (GRFT) (from red marine alga *Griffithsia* sp.) (van der Meer, de Haan, Schuurman, Haijema, Peumans et al. 2007; O'Keefe et al. 2010). However, only GRFT has been evaluated against SARS-CoV and MERS-CoV. This protein binds to multiple sites of SARS-CoV and MERS-CoV glycoproteins with high affinity and inhibits viral entry (O'Keefe et al. 2010; Millet et al. 2016). Additionally, this lectin also reduced the mortality and the severity of lethal pulmonary infection induced by SARS-CoV in mice. This effect is associated with the decrease of proinflammatory cytokines in infected lung tissue (O'Keefe et al. 2010).

Despite the potential antiviral activity of the aforementioned lectins, some limitations should be considered regarding their therapeutic utility. One practical issue is the rapid degradation of these macromolecules, imposing the need for multiple doses to maintain a therapeutic level. This obstacle could be addressed by the incorporation of the protein in formulations that promote controlled released and protection from denaturing agents (da Cunha et al. 2016; Yang et al. 2019; Tyo et al. 2020).

Other relevant concern is the recognition of glycoconjugates present in host cells since they could share same structural patterns

**Table I.** Antiviral activity of some lectins against SARS-CoV, MERS-CoV and other types of coronavirus

Lectin	Source	Sugar affinity	Anti-SARS-CoV-2 action	Anti-SARS-CoV action	Anti-MERS-CoV action	References
FRIL	<i>Lablab purpureus</i>	Man/Glu	In vitro	—	—	Liu et al. (2020b)
APA	<i>Allium porrum</i>	Man	—	In vitro	—	Keyaerts et al. (2007)
Morniga M II	<i>Morus nigra</i>	Man	—	In vitro	—	Keyaerts et al. (2007)
EHA	<i>Epipactis helleborine</i>	Man	—	In vitro	—	Keyaerts et al. (2007)
UDA	<i>Urtica dioica</i>	GlcNAc	—	In vivo and in vitro	—	Keyaerts et al. (2007); Day et al. (2009); Kumaki et al. (2011)
NICTABA	<i>Nicotiana tabacum</i>	GlcNAc	—	In vitro	—	Keyaerts et al. (2007)
Con A	<i>Canavalia ensiformis</i>	Man/Glu	—	—	—	Greig and Bouillant (1977); Nguyen et al. (1987)
HHA	<i>Hippeastrum hybrid</i>	Man	—	In vitro	—	van der Meer, de Haan, Schuurman, Haijema, Peumans et al. (2007); van der Meer, de Haan, Schuurman, Haijema, Verheije et al. (2007)
GNA (or GNL)	<i>Galanthus nivalis</i>	Man	—	In vitro	—	Hsieh et al. (2010)
Cyanovirin-N	<i>Nostoc ellipsosporum</i>	Man	—	—	—	van der Meer, de Haan, Schuurman, Haijema, Peumans et al. (2007)
Griffithsin	<i>Griffithsia</i> sp.	Man	—	In vivo and in vitro	In vitro	Millet et al. (2016); O'Keefe et al. (2010)

Man, mannose; GlcNAc, N-acetylglucosamine; Glu, glucose.



observed in viral glycoproteins due their synthesis by host machinery (Cipollo and Parsons 2020). The action of lectins on these unwanted targets could induce hemagglutination, intravascular agglutination of cells, cell proliferation and impaired immune responses. Even the positive results from animal models need to be examined with the appropriated caution, given the clear differences among the in vivo model species (most notably the mouse-adapted strains) and the original viruses.

### Strategies of protein engineering to improve the therapeutic application of lectins

The mitogenicity and proinflammatory properties of lectins (Jandu et al. 2017; Carvalho et al. 2018) raise several questions regarding their value to treat clinical conditions with severe inflammatory components, as seen in COVID-19 (Ye et al. 2020). Several attempts to overcome these issues have been performed, including protein engineering techniques. In this sections, we present the results obtained with GRFT and cyanovirin-N that showed action against coronaviruses (van der Meer, de Haan, Schuurman, Haijema, Peumans et al. 2007; O'Keefe et al. 2010). The data obtained with the derivative agents from BanLec (from banana) and microvirin (MVN) (isolated from the cyanobacterium *Mycrocystis aeruginosa*) toward other enveloped viruses are also discussed (Shahid et al. 2020; Swanson et al. 2015). These studies are summarized in Table II. The broad-spectrum activity of these agents and the techniques used in their design should be considered in the search for anti-infective compounds toward SARS-CoV-2.

### GRFT derivatives

GRFT is a jacalin-related lectin found as domain-swapped dimers with six identical carbohydrate-binding sites (three in each monomer) (Ziolkowska et al. 2006; Lee 2019). The dimerization promotes a multivalent interaction with mannose residues in the envelope glycoproteins and are essential for its antiviral action (Moulai et al. 2010). It has shown in vitro and in vivo actions against MERS-CoV, SARS-CoV and other coronaviruses, which make it a promising molecule for SARS-Cov-2 treatment (Lee 2019; Mani et al. 2020).

The monomeric forms of GRFT (mGRFT) were engineered in tandem repetitions leading to obtention of new proteins with two, three or four copies, designed as mGRFT tandemers. Cell-based assays showed that 3mGRFT and 4mGRFT tandemers exhibited higher antiviral activity against HIV when compared to 2mGRFTs and native GRFT. The linker between each unit of mGRFT allowed strong interaction of carbohydrate-binding domains with the oligosaccharides in the virion surfaces, without inducing viral aggregation (Moulai et al. 2015).

In another study, the antiviral action of oligomeric tandemers (2mGRFT and 3mGRFT) and native GRFT was assessed against Nipah virus (NiV; *Paramyxoviridae*), which is an emerging etiologic agent of respiratory diseases and fatal human encephalitis. The authors also evaluated the action a recombinant form with improved resistance to oxidation designated as Q-GRFT (Met78 → Gln). The 3mGRFT showed the highest anti-NiV effects among the tested GRFT versions, with more efficacy in preventing syncytia formation. Interestingly, the prophylactic intranasal administration of Q-GRFT induced more protection than 3mGRFT in a lethal model of intranasal infection using golden Syrian hamsters (Lo et al. 2020).

### Cyanovirin-N derivatives

Cyanovirin-N is one of the lectins with activity against coronaviruses and others enveloped viruses (Barriento et al. 2006; van der Meer, de Haan, Schuurman, Haijema, Peumans et al. 2007; Smeets et al. 2008; Kachko et al. 2013; Hu et al. 2015). This protein has two domains and can be found as monomers in solution (with two sugar-binding sites) or domain-swapped dimers when crystalized (with four sugar-binding sites). The dimerization was shown to restore the viral inhibition of mutants (Matei et al. 2010).

The antiviral activity of the designed cyanovirin-N oligomers (dimers, trimers and tetramers) was evaluated against HIV. The dimers showed higher anti-HIV efficacy than the parental protein and other forms. Importantly, the dimers exhibited neutralizing activity at comparable or even superior levels than antibodies (Keeffe et al. 2011). A similar approach was later reported based in the construction of "Nested" dimers of cyanovirin-N by rational design resulting in enhanced anti-HIV activity in comparison to the wild-type protein (Woodrum et al. 2016).

Other strategy was based on the addition of poly(ethylene glycol) (PEGylate) to reduce the immunogenicity and cytotoxicity of cyanovirin-N as well as to enhance its half-time in plasm (Zappe et al. 2008; Chen et al. 2014; Wu et al. 2015). For instance, a recombinant form of cyanovirin-N with a flexible and hydrophilic linker (Gly4Ser)<sub>3</sub> at the N-terminus (denominated LCVN) was produced and then PEGylated in its N-terminal  $\alpha$ -amine, resulting in the 10 K PEG-aldehyde (ALD)-LCVN. Both cyanovirin-N derivatives exhibited anti-HIV-1 activity with reduced cytotoxicity; however, the mono-PEGylated version still showed the best results (Chen et al. 2014).

Later, a new form of mono-PEGylated cyanovirin-N (PEG20k-LCVN) was described as a potent anti-influenza A inhibitor. PEG20k-LCVN showed higher action than ribavirin. The usefulness of PEG20k-LCVN was shown in infection models using mice and chicken embryos infected by influenza H3N2. The infected mice treated with PEG20k-LCVN showed an improved life span associated with the reduction of viral genome expression and attenuation of lung damage (Wu et al. 2015).

The derivative PEG10k-LCVN also inhibited normal and acyclovir-resistant strains of HSV-1, even though with less action than its precursors (wild-type and linked-cyanovirin-N). Despite of this, the reduction in cytotoxicity, antigenicity and mitogenicity observed for the PEGylated version are important aspects that advocate for its therapeutic value (Lei et al. 2019). Overall, these results with mono-PEGylated derivatives represent alternative models to increase the usefulness of lectins in antiviral therapy.

### Recombinant BanLec (H84T)

BanLec is a mannose-binding protein from the group of lectin-related jacalin with tetrameric structure (two binding sites in each monomer) and remarkable anti-infective activity toward enveloped viruses (Meagher et al. 2005; Swanson et al. 2010; Hopper et al. 2017; de Camargo et al. 2020). A single amino acid replacement at position 84 (histidine replacement by threonine) impaired the mitogenic action without altering its ability to bind to mannose residues present at viral glycoproteins (Swanson et al. 2015).

These positive effects were attributed to a reduction in the multivalent lectin-glycan interactions that are associated with the proliferative induction (Swanson et al. 2015). The engineered BanLec (H84T) has shown in vitro and in vivo antiviral activities against HIV, hepatitis C virus (HCV), influenza and Ebola (Swanson et al. 2015; Covas-Datson et al. 2019, 2020).

**Table II.** Some examples of engineered proteins derived from antiviral lectins

Native lectin	Source	Sugar affinity	Type(s) of derivative(s)	Action	References
Griffithsin	<i>Griffithsia</i> sp.	Man	Monomeric and (mGRFT) oligomeric tandem forms (2mGRFT, 3mGRFT and 4mGRFT)	3mGRFT and 4mGRFT exhibited improved in vitro anti-HIV action 3mGRFT showed improved action toward NIV	Moulaei et al. (2015) Lo et al. (2020)
Cyanovirin-N	<i>Nostoc ellipsosporum</i>	Man	Q-GRFT Oligomers (dimers, trimers and tetramers) PEGylated versions	Q-GRFT has higher resistance to oxidation and in vivo anti-NIV action The dimers showed highest anti-HIV efficacy 10 K PEG-ALD-LCVN has improved anti-HIV and anti-HSV-1 actions PEG20k-LCVN has improved anti-influenza H3N2 action In vitro inhibition of HIV In vitro dual inhibition of HIV	Lo et al. (2020) Keefe et al. (2011); Woodrum et al. (2016) Chen et al. (2014); Lei et al. (2019) Wu et al. (2015) McFadden et al. (2007) Contarino et al. (2013); Parajuli et al. (2016, 2018) Swanson et al. (2015); Covese-Datson et al. (2019, 2020)
BanLec	<i>Musa</i> sp.	Man	Chimera L5 (cyanovirin-N and 12p1) DAVEI: Chimeric cyanovirin-MPER formulation Recombinant BanLec (H84T)	The mutation impaired the mitogenic activity. rBanLec showed antiviral action against HIV, HCV, influenza and Ebola	Swanson et al. (2015); Covese-Datson et al. (2019, 2020)
Microvirin	<i>Mycrocystis aeruginosa</i>	Man	Oligomers (dimers, trimers and tetramers) LUMS1 with two identical structural domains MVN*	Trimers and tetramers exhibited improved in vitro anti-HCV action Although LUMS1 has lower cytotoxicity and immunogenicity than native MVN, it showed lower anti-HIV and anti-HCV actions MVN* has two mutations (Q81K and M83R) that resulted in higher affinity to mannose residues and lower mitogenicity	Min et al. (2017) Shahid et al. (2020) Ang et al. (2020)
Actinohivin	<i>Longispora albida</i>	Man	MVN*–DAVEI (second generation): Fusion of MPER with MVN* Avaren Lectibody: VRC01 <sub>Fab</sub> –Avaren Lectibody: AvFc	In vitro dual inhibition of HIV It has improved solubility and pharmacological activity In vitro neutralization of HIV In vitro neutralization of HIV. Inhibition of SIV infection in <i>Rhesus macaques</i>	Parajuli et al. (2018); Ang et al. (2020) Hamorsky et al. (2019) Seber Kasinger et al. (2019) Hamorsky et al. (2019)

Man, mannose; NIV, Nipah virus; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus; HCV, hepatitis C virus; SIV, simian immunodeficiency virus; VRC01<sub>Fab</sub>, antigen-binding fragment (Fab) of the CD4 binding site-specific bNAbs VRC01; AvFc, fusion of Avaren and human the fragment crystallizable region (Fc) of the human immunoglobulin G1 (Fc-IgG1); MPER, membrane-proximal external region (MPER) of HIV-1 gp41.

### MVN derivatives

MVN is a monomeric lectin that exhibits two domains (A and B) with 35% of sequence similarity, and it is able to neutralize some viruses (HIV, HCV) due to the binding to high-mannose type N-glycan present in envelope proteins. Some *in vitro* data suggest that MVN induces lower toxicity and cell proliferation than cyanovirin-N (Huskens et al. 2010; Shahzad-ul-Hussan et al. 2011; Kachko et al. 2013; Min et al. 2017).

In order to improve the inhibitory action of MVN, some oligomeric versions of this lectin were designed and tested *in vitro* against HCV. The results showed that tri- and tetramers have higher ability to block the HCV invasion than dimers and monomers (Min et al. 2017). Recently, a version of MVN (LUMS1) was engineered to have two identical domains and, therefore, two carbohydrate-binding sites. Although LUMS1 showed lower sugar affinity than wild-type, it was able to block HIV and HCV infectivity. Undoubtedly, the most advantageous characteristics of LUMS1 are its lower cytotoxicity and immunogenicity. These properties should be associated to the structural homogeneity conferred by the two identical domains (Shahid et al. 2020).

### Chimeras derived from antiviral lectins

The production of chimeras using the cyanobacterium-derived lectins (cyanovirin-N or recombinant MVN) is another interesting strategy that has been largely exploited for HIV therapy (McFadden et al. 2007; Contarino et al. 2013; Parajuli et al. 2016, 2018). A chimera (L5) was formulated using cyanovirin-N and a linear peptide (12p1) aiming to target the envelope gp120 glycoprotein with synergistic action. For this purpose, 12p1 was fused to the C-terminal domain of cyanovirin-N. The chimera L5 significantly inhibited the binding of HIV to the host cell receptor protein (McFadden et al. 2007).

Other chimeras were constructed with the fusion of cyanobacterial lectins (cyanovirin-N or MVN) and peptides derived from the membrane-proximal external region (MPER) of HIV-1 gp41 glycoprotein (Contarino et al. 2013; Parajuli et al. 2016, 2018; Ang et al. 2020).

The chimeras were intended to inhibit viral binding to its receptor (through lectin portion) and induce viral inactivation and were called as dual-acting virucidal entry inhibitor (DAVEI) (Contarino et al. 2013). The experimental data showed that the chimeras promoted simultaneous engagement of gp120 and gp41 domains and lead to the irreversibly lytic inactivation of HIV. However, the mechanism involved in the DAVEI action is not completely understood (Parajuli et al. 2016, 2018).

The MVN-based DAVEI is considered a second-generation chimera due its lower mitogenicity in comparison to cyanovirin-N. The authors further improved this characteristic by designing a version of MVN\* with two mutations (Q81K and M83R), which resulted in higher affinity to mannose residues (Huskens et al. 2010; Parajuli et al. 2018). MVN\*-DAVEI was able to induce disruption of any membrane containing the HIV Env glycoprotein (Ang et al. 2020).

### Lectibodies

Active lectins could be also fused with broadly neutralizing antibodies (bNAbs) to develop potent bispecific antiviral agents. The idea of “lectibody” was experimentally applied for anti-HIV therapy using the Avaren recombinant protein. Avaren is derived from an antiviral lectin isolated from the actinomycete *Longispora albida* K97-0003T

known as actinohivin (Hamorsky et al. 2019; Hoorelbeke et al. 2010; Seber Kasinger et al. 2019). Avaren is expressed in the plant *Nicotiana benthamiana* and it was designed to have improved solubility and pharmacological activity than its parental lectin. These enhanced features were achieved by modifying 17 amino acid residues and by introducing a disulfide bond in the sugar-binding sites of domains 1 and 3 (the disulfide bond is found in the domain 2 of actinohivin) (Hamorsky et al. 2019).

In the first report, Avaren was fused to the antigen-binding fragment (Fab) of the CD4 binding site-specific VRC01 bNAb, which resulted in the VRC01<sub>Fab</sub>-Avaren lectibody. In this case, VRC01<sub>Fab</sub>-Avaren was designed to: (i) target the mannose residues present in the HIV-1 gp120 glycoprotein and (ii) the binding site of gp120 on the receptor of TCD4 lymphocytes (through Avaren and VRC01, respectively). Using cell-based assays, the authors proved the bispecific neutralization of HIV by VRC01<sub>Fab</sub>-Avaren and showed that the lectibody had stronger activity than the isolated agents (Seber Kasinger et al. 2019).

The second lectibody was generated by the fusion of Avaren and the crystallizable region fragment (Fc) of the human immunoglobulin G1 (Fc IgG1). It was called AvFc and showed higher affinity (approximately 10-fold) to gp120 than actinohivin. AvFc also showed higher *in vitro* activity toward several strains of HIV-1 and HIV-2 than its wild-type counterpart. Employing biochemical assays, the authors showed the bispecific function of AvFc: (i) the treatment with mannosidases impaired its antiviral activity and (ii) a mutant of AvFc with reduced affinity to Fcγ receptors also showed lower action than AvFc. This lectibody did not induce toxic effects to human and mice peripheral blood mononuclear cells (PBMC). Finally, AvFc was effective in an infection model of simian immunodeficiency virus (SIV) in *Rhesus macaques* (Hamorsky et al. 2019).

In general, the advances obtained in these studies with engineered lectins provide several lessons that could be applied in the development of therapeutic strategies against COVID-19. However, the possible adverse effects related to systemic administration due to systemic administration of carbohydrate-binding agents need to be carefully assessed for each type of infection. In the context of COVID-19, the intranasal administration of these agents seems to be an attractive option. However, some aspects are also important to be examined, including the tissue distribution of these macromolecules (associated with their size), their influence in tissue metabolism, engagement of cells receptors and induction of local inflammation (especially in the lower respiratory tract).

### Lectins can be used as adjuvant for vaccines

The implementation of global community immunity using vaccines is believed to be the best and safest strategy for the management and eradication of SARS-CoV-2 (Corey et al. 2020). Since the beginning of this epidemic, several academic and industrial groups have made considerable efforts to design effective vaccines (Cohen 2020). According to vaccine tracking data from the Milken Institute, as of 18 July 2020, a total of 198 projects are in development for COVID-19, of which 18 candidates are already in the clinical phase and the others are in preclinical or exploratory phases.

The vaccines are distributed in the following categories: (i) live attenuated virus: 4; (ii) inactivated virus: 13; (iii) RNA-based: 26; (iv) DNA-based: 16; (v) protein subunit: 63; (vi) nonreplicating viral vector: 23; (vii) replicating the viral vector: 18; (ix) virus-like particles: 14; (x) replicating bacterial vector: 1 and (xi) unknown

category (those that not fail in the groups or the details are not described): 20. There are at least three vaccine candidates in phase III clinical trials: AZD1222 (formally known as ChAdOx1 nCoV-19), an adenovirus-vectored vaccine encoding the spike protein of SARS-CoV-2 which is developed by the University of Oxford in partnership with AstraZeneca (British pharmaceutical company); Coronavac, a vaccine using inactivated virus from Sinovac Biotech (Chinese biotechnology company) and mRNA-1273, a mRNA-based vaccine encoding the spike protein of SARS-CoV-2, which is manufactured by Moderna Therapeutics (American Company) (Jackson et al. 2020; van Doremalen et al. 2020).

The majority of these initiatives are focused on the development of gene-based vaccines (including viral or nucleic acid vectors which encode protein antigens that are produced by host cells) and protein-based vaccines (using recombinant or synthetic antigenic proteins or subdomains, or viral proteins assembled as virus-like particles) (Gao et al. 2020; Peeples 2020). The biggest challenge with these types of vaccines is the induction of long-lasting immunity, which is usually lower than the traditional approaches using live or inactivated organisms (Vetter et al. 2018; Shi et al. 2019).

In this scenario, the employment of powerful adjuvants is important to improve immunization efficacy. These compounds need to enhance the immune response induced by the vaccine, while keeping the equilibrium between humoral and cellular immune responses (Del Giudice et al. 2018; Shi et al. 2019). Noteworthy to mention that even the proper induction of Th1-biased response, which is important for protection against viral infections, still remains as a limitation for some adjuvants (Golos and Lutynska 2015).

Lectins are well-known to promote proliferation of lymphocytes and modulate the release of effector molecules (cytokines and nitric oxide) by immune cells. For instance, several lectins are reported as potent inducers of IL-12 and IFN- $\gamma$  production, which are key cytokines in the establishment of Th1 axis (da Silva et al. 2015; Oliveira Brito et al. 2017; de Souza Feitosa Lima et al. 2019; Ruterbusch et al. 2020). Some lectins can also bind to toll-like receptors and/or increase their expression levels, which may also modulate the release of proinflammatory cytokines and increase the receptor's ability to recognize the pathogens (da Silva and Correia 2014; Batista et al. 2017; Ricci-Azevedo et al. 2017).

In fact, the enhancement of Th1-biased immune response is important for protective immunity against viruses and other intracellular pathogens due to the activation of cytotoxic cells (natural killer cells and TCD8 lymphocytes) and production of neutralizing antibodies involved in immunological memory (Ruterbusch et al. 2020). In this sense, the immunomodulatory properties of lectins make them attractive candidates for vaccine adjuvants. This concept has been experimentally proven against different types of viral pathogens, including enveloped viruses such as hepatitis B virus, herpesvirus and influenza (Lavelle et al. 2002; Song et al. 2007; Gao et al. 2013; Reyna-Margarita et al. 2019) (Table III). In this section, some studies applying lectin as adjuvant for influenza vaccines are discussed.

The Korean mistletoe lectin C (KML-C) isolated from *Viscum album* coloratum completely protected mice against this H1N1 influenza when the lectin was intranasally administrated along with inactivated virus. KML-C significantly increased the levels of anti-influenza antibodies [immunoglobulin G (IgG) and immunoglobulin A (IgA)] and the population of influenza-specific lymphocytes in spleens and in mediastinal lymph nodes. Moreover, the mice immunized with KML-C and inactivated H1N1 also exhibited partial protection toward H3N2 challenge (Song et al. 2007). Other interesting effect of KML-C is the increase of perforin expression,

an important cytotoxic protein secreted by natural killer cells and TCD8 lymphocytes (Kim et al. 2018).

The AAL molecule isolated from *Agrocybe aegerita* (mushroom) is another example of lectin with adjuvant properties for influenza immunization. In this study, mice were immunized by subcutaneous injection of inactivated H9N2 strain and AAL. The animals that received AAL and inactivated H9N2 exhibited higher levels of anti-influenza IgG1 and immunoglobulin G2a (IgG2a) than those treated with inactivated virus alone. By employing a recombinant-AAL with mutation in the carbohydrate-binding domain, the authors also showed that the adjuvant properties of AAL were mediated by the recognition of glycoproteins in the viral surface (Ma et al. 2017). Transcriptome analysis revealed that the adjuvant effects of AAL were associated with an increased expression of genes related to leukocyte migration and lymphocyte activation (Ma et al. 2018).

Although these studies show the lectins as promisor adjuvant candidates, the concerns regarding their administration listed before (agglutination of host cells, induction of undesired inflammation and proliferation) need to be considered. Specifically, long-term immunological and toxicological evaluations are required to prove the usefulness of an adjuvant compound (Shah et al. 2017). The potential induction of severe systemic inflammation by lectins is also a possibility to be evaluated in the early stage of the research. Regarding the application of lectins as adjuvants for viral vaccines (including those against SARS-CoV-2), one important challenge is to choose of a combination (vaccine/lectin) able to concomitantly promote an effective adaptive immune response with clinical safety.

### Lectin-based devices for identification of glycosylation changes in viral and host proteins

The incorporation of glycans in envelope proteins has great influence in viral adhesion and recognition by the immune system since epitopes of neutralizing antibodies are often protected by glycan molecules (Watanabe et al. 2019; Vankadari and Wilce 2020). The differential patterns of glycosylation in a viral protein can be elucidated by lectin-based devices, e.g. lectin-microarrays and lectin-ELISA assays. This information is essential to expand our understanding about the role played by glycan shields in viral pathogenesis (Guo et al. 2018; Wagatsuma et al. 2018; Hiono et al. 2019; Thompson et al. 2020).

The comprehension of glycosylation of host proteins is other hot topic to be considered in the context of infectious diseases (Goncalves et al. 2019; Irvine and Alter 2020; Kaplan and Vincent 2020). The dynamic of glycosylation has been evaluated for a plethora of viral diseases (Qin et al. 2016, 2017; Dalal et al. 2019; Major and Law 2019). In some cases, specific differential expression of these glycoconjugates is correlated with the severity degree of some conditions (Luna et al. 2014; Yeh et al. 2019). These experimental approaches are important to discovery and clinical validation of glycoconjugates as biomarkers for diagnosis.

The possible correlation among alterations in serum glycoproteins expression (and/or in their glycosylation patterns) and the clinical presentations of COVID-19 is another question that could be addressed by employing lectin-based tools such as lectin-affinity chromatography, lectin-microarrays and lectin-immunoassays (lectin-ELISA). So far, some studies have associated changes in the serum constituents of patients with COVID-19 and disease severity. For example, serum levels of IL-6 and C-reactive protein had a significant correlation with the severity of the disease, while the



**Table III.** Examples of lectins used as adjuvant for antiviral vaccines

Lectin	Source	Sugar affinity	Administration	Type of vaccine	References
KML-C	<i>Viscum album coloratum</i> (Korean mistletoe)	Gal and GalNAc	Intranasal route in mice	Inactivated vaccine for influenza H1N1	Song et al. (2007); Kim et al. (2018)
AAL	<i>Agrocybe aegerita</i>	GlcNAc	Subcutaneous route in mice	Inactivated vaccine for influenza H9N2	Ma et al. (2017)
POL	<i>Pleurotus ostreatus</i>	GalNAc	Intramuscular route in mice	DNA vaccine for HBV	Gao et al. (2013)
MLI, MLII and MLIII	<i>V. album L.</i> (European mistletoe)	Gal and GalNAc	Intranasal route in mice	Subunit vaccine (glycoprotein D2) for HSV	Lavelle et al. 2002

GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; Gal, Galactose; Man, mannose.

**Table IV.** Examples of lectins used for development of biosensor and LAP

Lectin	Source	Sugar affinity	Type of application	References
Con A	<i>Canavalia ensiformis</i>	Man/Glu	Biosensor for viral detection Biosensor for detection of serum glycoproteins	Hong et al. (2015); Simao et al. (2020) Oliveira et al. (2009); Luna et al. (2014)
Cramoll	<i>Cratylia mollis</i>	Man/Glu	Biosensor for detection of serum glycoproteins	Oliveira et al. (2011); Avelino et al. (2014)
BmolL	<i>Baubinia monandra</i>	Gal	Biosensor for detection of serum glycoproteins	Andrade et al. (2011)
GNA (or GNL)	<i>Galanthus nivalis</i>	Man	LAP	Tullis et al. (2010); Koch et al. (2018)

Gal, Galactose; Glu, glucose; Man, mannose; LAP, lectin affinity plasmapheresis.

procalcitonin (a glycoprotein) may be a predictor of poor/good prognosis (Liu et al. 2020a).

## Lectin-based biosensors

The development of fast and sensitive methods for pathogens detection is essential to promote the effective treatment and to prevent their dissemination (Liang et al. 2020; Qiu et al. 2020; Seo et al. 2020). The techniques currently used for viral diagnosis comprise immunochromatography-based assays, ELISA and polymerase chain reaction (PCR and derivative assays). However, especially in the context of COVID-19, some serological tests do not exhibit satisfactory accuracy, while the molecular assays require expensive reagents and extensive sample preparation, which may cause a delay in results (Acquah et al. 2016; Cesewski and Johnson 2020).

Biosensors are analytical tools that have a bioreceptor element (such as a lectin) immobilized in a thin layer on the surface of the transducer. They are intended to provide specific and sensitive detection of an analyte in biological samples (Silva 2018, de Oliveira et al. 2019). A few biosensors have been proposed for the SARS-CoV-2 diagnosis targeting S-protein (Seo et al. 2020) or nucleic acids (Qiu et al. 2020). In this sections, we discuss the construction of lectin-based biosensors targeting viral or host glycoproteins (Table IV).

### Biosensors for viral glycoproteins

The intrinsic specificity of lectins toward glycans allows their use as an element of biorecognition of glycans present in viral proteins (Hong et al. 2015; Tung et al. 2019; Cesewski and Johnson 2020). In the case of SARS-CoV-2, its envelope glycoproteins could be

also exploited for identification using lectin-based biosensors (as illustrated in the Supplementary Figure S2C).

An electrochemical biosensor based on Con A-modified nanostructured gold electrodes was used to detect norovirus (nonenveloped virus) in fecal samples using cyclic voltammetry and impedance spectroscopy analyses. This biosensor showed high specificity and did not exhibit crossreaction with hepatitis A or E viruses (Hong et al. 2015). Another example of electrochemical biosensor was elaborated using cysteine, zinc oxide nanoparticles and Con A. The impedimetric response allowed the distinction of DENV-2, Zika virus, chikungunya virus and yellow fever virus in serum samples (Simao et al. 2020).

### Biosensors for detection of glycan patterns in infected individuals

Some studies have suggested that glycoproteins are differentially expressed in the serum of subjects affected by acute and chronic viral infections (such as dengue and hepatitis), making the profile of serum glycoproteins an emerging target for diagnosis (Luna et al. 2014; Yeh et al. 2019). In this scenario, biosensors incorporated with lectins could provide a fast identification of people infected with SARS-CoV-2 based on the profile of glycoproteins in biological fluids. This approach could be extremely interesting if SARS-CoV-2-infected subjects exhibited a differential glycosylation profile than those individuals infected by other respiratory pathogens.

Two types of Con A-based biosensors have been proposed for dengue diagnosis using serum glycoproteins. In the first, Con A was immobilized on gold electrode using polyvinyl butyral to construct a biosensor capable to identify different glycoprotein patterns in the sera of patients with dengue fever and dengue hemorrhagic fever.

The distinction was based on changes in charge transfer resistance using electrochemical impedance spectroscopy (Oliveira et al. 2009). The other system was designed using Con A and lipid membranes for differentiation of glycoproteins from the serum of individuals infected with DENV-1, DENV-2 and DENV-3. The differentiation of the pattern of serum glycoproteins from the subjects infected by each serotype was based in impedimetric analysis, with higher response to DENV-3 infection (Luna et al. 2014).

Cramoll, a glucose/mannose-binding lectin extracted from *Cratylia mollis* seeds, is another lectin used in biosensors for dengue diagnosis. It was used in two types of biosensors employing: (i) gold electrodes modified with Fe<sub>3</sub>O<sub>4</sub> nanoparticles and polyvinyl butyral (Oliveira et al. 2011) and (ii) gold nanoparticles/polyaniline electrodes (Avelino et al. 2014). Similarly, the galactose-specific lectin isolated from *Bauhinia monandra* leaves (BmoLL) was immobilized on gold nanoparticles-polyaniline hybrid composite (Andrade et al. 2011). All these lectin-derived sensors were effective in correlating the glycosylation patterns of serum proteins with the type of infection.

These lectin-based biosensors could represent a more cost-effective alternative when compared to those that currently use antibodies and nucleic acids (Luna et al. 2014). However, their sensitivity and specificity could be a limitation. In particular, the binding to glycans from other sources (host or other pathogens) could induce false results. Thus, these parameters need to be effectively optimized prior their use in clinical analysis.

### Lectin affinity plasmapheresis for extracorporeal viral elimination

Plasmapheresis is the extracorporeal purification of pathogens and other products (toxins, cytokines) from blood. This could be performed in association with dialysis as a resource to reduce SARS-CoV-2 levels in the patient's blood (Turgutkaya et al. 2020). Indeed, this technique has been used to remove SARS-CoV-2 from convalescent plasma transfusions (Li et al. 2020b) and has been considered as an alternative treatment considered for COVID-19 due to the absence of vaccine or specific medication for SARS-CoV-2 (Brown and McCullough 2020; Duan et al. 2020).

The ability of GNA to bind mannose-containing glycans has been used to modify the plasmapheresis apparatus (Hemopurifier® cartridges) (Supplementary Figure S2D). The system is designed as a lectin affinity plasmapheresis (LAP) and has been employed in the in vitro and clinical evaluations of the viral disease. For instance, GNA-modified hemopurifier removed HCV from blood of HCV-infected patients. In vivo analysis showed that the association of this system with dialysis was effective in reducing HCV load in the blood (Tullis et al. 2009).

Later, other study showed that the continuous blood purification using LAP resulted in undetectable viral load in HCV-positive patients. This therapy enhanced the effectiveness of standard drugs without plasma losses (Tullis et al. 2010). A GNA-based system was also successfully applied for the extracorporeal removal of Ebola virus in a patient (Buttner et al. 2014). In addition to these cases, in vitro analysis with LAP devices cleared MERS-CoV and Marburg virus as well as their respective soluble glycoproteins (Koch et al. 2018).

Although the number of tested patients in these studies is rather limited, these results with LAP shall be considered for future applications of lectins in clinical settings (Table IV). Further evaluation of fluid composition after the procedures is performed needs to be conducted to rule out the possibility of removal of other important

plasmatic proteins, in special neutralizing antibodies. The efficiency of these devices should be compared with other assays of pathogen inactivation.

### Conclusions and perspectives

The presence of glycoproteins in the viral envelope opens a wide range of possibilities for application of lectins to solve different types of problems involved with viral infections such as COVID-19. In the therapeutic area, the lectins could be considered leading molecules for the development of new antiviral approaches due to their ability to inhibit viral entry in the host cell. The advances in protein design strategies are important to boost the clinical application of these agents considered for treatment of SARS-CoV-2 and other viral infections. The immunomodulatory action of some lectins can also be exploited to improve the effectiveness of immunization schemes for viral infections.

On the other hand, lectin-carbohydrates interactions can be used to design devices for diagnosis targeting viral glycoproteins or host glycoproteins alterations during viral infections. These apparatuses hold the promise to provide fast, sensitive and cost-effective identification of infected individuals and are of vital need during pandemic situations, as imposed for COVID-19. Finally, the LAP is an interesting resource for blood purification and to help the implementation of convalescent plasma therapy.

The major limitation for these diverse applications is the possible binding of this lectin in unwanted glycosylated targets. For instance, the administration of lectins could result in the agglutination and proliferation of cells besides the exacerbation of immune response. Similarly, the lectin-based biosensors could have low specificity due the signals from other glycans. Several interesting strategies have been applied to overcome these issues.

### Supplementary data

Supplementary data are available at *Glycobiology* online.

### Funding

This work was funded by Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão (FAPEMA; process code: COVID-19-00768/20), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and European Commission (ZIKAlliance H2020 734548).

### Conflict of interest

None declared.

### References

- Acquah C, Danquah MK, Agyei D, Moy CK, Sidhu A, Ongkudon CM. 2016. Deploying aptameric sensing technology for rapid pandemic monitoring. *Crit Rev Biotechnol.* 36:1010–1022.
- Ahmed SF, Quadeer AA, McKay MR. 2020. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. *Viruses.* 12.
- Alanagreh L, Alzoughool F, Atoum M. 2020. The human coronavirus disease COVID-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. *Pathogens.* 9:331.
- Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. 2020. The proximal origin of SARS-CoV-2. *Nat Med.* 26:450–452.

- Andrade CA, Oliveira MD, de Melo CP, Coelho LC, Correia MT, Nogueira ML, Singh PR, Zeng X. 2011. Diagnosis of dengue infection using a modified gold electrode with hybrid organic-inorganic nanocomposite and *Bauhinia monandra* lectin. *J Colloid Interface Sci.* 362:517–523.
- Ang CG, Hossain MA, Rajpara M, Bach H, Acharya K, Dick A, Rashad AA, Kutzler M, Abrams CF, Chaiken I. 2020. Metastable HIV-1 surface protein Env sensitizes cell membranes to transformation and Poration by dual-acting Virucidal entry inhibitors. *Biochemistry.* 59:818–828.
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, et al. 2020. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N Engl J Med.*
- Avelino K, Andrade C, De Melo C, Nogueira M, Correia M, Coelho L, Oliveira M. 2014. Biosensor based on hybrid nanocomposite and CramoLL lectin for detection of dengue glycoproteins in real samples. *Synth Met.* 194:102–108.
- Bagdonaite I, Vakhrushev SY, Joshi HJ, Wandall HH. 2018. Viral glycoproteomes: Technologies for characterization and outlook for vaccine design. *FEBS Lett.* 592:3898–3920.
- Bagdonaite I, Wandall HH. 2018. Global aspects of viral glycosylation. *Glycobiology.* 28:443–467.
- Barrientos LG, Matei E, Lasala F, Delgado R, Gronenborn AM. 2006. Dissecting carbohydrate-cyanovirin-N binding by structure-guided mutagenesis: Functional implications for viral entry inhibition. *Protein Eng Des Sel.* 19:525–535.
- Batista J, Ralph MT, Vaz RV, Souza P, Silva AB, Nascimento D, Souza LT, Ramos MV, Mastroeni P, Lima-Filho JV. 2017. Plant lectins ConBr and CFL modulate expression toll-like receptors, pro-inflammatory cytokines and reduce the bacterial burden in macrophages infected with salmonella enterica serovar typhimurium. *Phytomedicine.* 25:52–60.
- Battle D, Wysocki J, Satchell K. 2020. Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy? *Clin Sci (Lond).* 134:543–545.
- Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S. 2020. Sars-CoV-2 envelope and membrane proteins: Structural differences linked to virus characteristics? *Biomed Res Int.* 2020:4389089.
- Brown BL, McCullough J. 2020. Treatment for emerging viruses: Convalescent plasma and COVID-19. *Transfus Apher Sci.* 102790.
- Brown GD, Willment JA, Whitehead L. 2018. C-type lectins in immunity and homeostasis. *Nat Rev Immunol.* 18:374–389.
- Buttner S, Koch B, Dolnik O, Eickmann M, Freiwald T, Rudolf S, Engel J, Becker S, Ronco C, Geiger H. 2014. Extracorporeal virus elimination for the treatment of severe Ebola virus disease—First experience with lectin affinity plasmapheresis. *Blood Purif.* 38:286–291.
- Carbaugh DL, Lazear HM. 2020. Flavivirus envelope protein glycosylation: Impacts on viral infection and pathogenesis. *J Virol.* 94:e00104–20.
- Carvalho E, Oliveira WF, Coelho L, Correia MTS. 2018. Lectins as mitosis stimulating factors: Briefly reviewed. *Life Sci.* 207:152–157.
- Cesewski E, Johnson BN. 2020. Electrochemical biosensors for pathogen detection. *Biosens Bioelectron.* 159:112214.
- Chen J, Huang D, Chen W, Guo C, Wei B, Wu C, Peng Z, Fan J, Hou Z, Fang Y, et al. 2014. Linker-extended native cyanovirin-N facilitates PEGylation and potentially inhibits HIV-1 by targeting the glycan ligand. *PLoS One.* 9:e86455.
- Chen N, Kong X, Zhao S, Xiaofeng W. 2020. Post-translational modification of baculovirus-encoded proteins. *Virus Res.* 279:197865.
- Cipollo JF, Parsons LM. 2020. Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships. *Mass Spectrom Rev.* 39:371–409.
- Coelho LC, Silva PM, Lima VL, Pontual EV, Paiva PM, Napoleao TH, Correia MT. 2017. Lectins, interconnecting proteins with biotechnological/pharmacological and therapeutic applications. *Evid Based Complement Altern Med.* 2017:1594074.
- Cohen J. 2020. Vaccine designers take first shots at COVID-19. *Science.* 368:14–16.
- Contarino M, Bastian AR, Sundaram RVK, McFadden K, Duffy C, Ganupomu V, Baker M, Abrams C, Chaiken I. 2013. Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1. *Antimicrob Agents Chemother.* 57:4743–4750.
- Corey L, Mascola JR, Fauci AS, Collins FS. 2020. A strategic approach to COVID-19 vaccine R&D. *Science.* 368:948–950.
- Cosset FL, Lavillette D. 2011. Cell entry of enveloped viruses. *Adv Genet.* 73:121–183.
- Coves-Datson EM, Dyal J, DeWald LE, King SR, Dube D, Legendre M, Nelson E, Drews KC, Gross R, Gerhardt DM, et al. 2019. Inhibition of Ebola virus by a molecularly engineered banana lectin. *PLoS Negl Trop Dis.* 13:e0007595.
- Coves-Datson EM, King SR, Legendre M, Gupta A, Chan SM, Gitlin E, Kulkarni VV, Pantaleon Garcia J, Smeets DF, Lipka E, et al. 2020. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. *Proc Natl Acad Sci U S A.* 117:2122–2132.
- da Cunha CR, da Silva LC, Almeida FJ, Ferraz MS, Varejao N, Cartaxo MF, de Miranda RC, de Aguiar FC Jr, Santos NP, Coelho LC, et al. 2016. Encapsulation into stealth liposomes enhances the antitumor action of recombinant *Cratylia mollis* Lectin expressed in *Escherichia coli*. *Front Microbiol.* 7:1355.
- da Silva LC, Alves NM, de Castro MC, Pereira VR, da Paz NV, Coelho LC, de Figueiredo RC, Correia MT. 2015. Immunomodulatory effects of pCramoll and rCramoll on peritoneal exudate cells (PECs) infected and non-infected with *Staphylococcus aureus*. *Int J Biol Macromol.* 72:848–854.
- da Silva LC, Correia MT. 2014. Plant lectins and toll-like receptors: Implications for therapy of microbial infections. *Front Microbiol.* 5:20.
- Dalal K, Dalal B, Bhatia S, Shukla A, Shankarkumar A. 2019. Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection. *Clin Chim Acta.* 495:309–317.
- Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smeets DF, Barnard DL. 2009. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. *Virology.* 395:210–222.
- de Camargo LJ, Picoli T, Fischer G, de Freitas ACO, de Almeida RB, da Silva Pinto L. 2020. Antiviral activity of native banana lectin against bovine viral diarrhea virus and bovine alphaherpesvirus type 1. *Int J Biol Macromol.* 157:569–576.
- de Oliveira FE, da Cunha CRA, Albuquerque PBS, de Paula RA, Aranda-Souza MA, Alves MS, Zagmignan A, Carneiro-da-Cunha MG, da Silva LCN, Dos Santos Correia MT. 2017. Lectin-carbohydrate interactions: Implications for the development of new anticancer agents. *Curr Med Chem.* 24:3667–3680.
- de Oliveira WF, Dos Santos Silva PM, Coelho L, Dos Santos Correia MT. 2019. Biomarkers, biosensors and biomedicine. *Curr Med Chem.* 27:3519–3533.
- de Souza Feitosa Lima IM, Zagmignan A, Santos DM, Maia HS, Dos Santos SL, da Silva CB, Vieira SL, Filho CMB, de Sousa EM, Napoleao TH, et al. 2019. Schinus terebinthifolia leaf lectin (SteLL) has anti-infective action and modulates the response of *Staphylococcus aureus*-infected macrophages. *Sci Rep.* 9:18159.
- Del Giudice G, Rappuoli R, Didierlaurent AM. 2018. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. *Semin Immunol.* 39:14–21.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A.* 117:9490–9496.
- Fung TS, Liu DX. 2018. Post-translational modifications of coronavirus proteins: Roles and function. *Futur Virol.* 13:405–430.
- Furukawa NW, Brooks JT, Sobel J. 2020. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. *Emerg Infect Dis.* 26.
- Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science.* 369:77–81.
- Gao W, Sun Y, Chen S, Zhang J, Kang J, Wang Y, Wang H, Xia G, Liu Q, Kang Y. 2013. Mushroom lectin enhanced immunogenicity of HBV DNA vaccine in C57BL/6 and HBsAg-transgenic mice. *Vaccine.* 31:2273–2280.

- Golos A, Lutynska A. 2015. Aluminium-adjuvanted vaccines—A review of the current state of knowledge. *Przegl Epidemiol.* 69(731–734):871–734.
- Goncalves BS, Horta MAP, Acero PHC, Bochner R, Lima MDRQ, de Araujo ES, Sampaio SA, Nogueira RMR, de Filippis AMB. 2019. Dynamics of nonstructural glycoprotein-1 in dengue patients presenting with different clinical manifestations from 1986 to 2012 in Rio de Janeiro, Brazil. *J Med Virol.* 91:555–563.
- Gondim ACS, da Silva SR, Mathys L, Noppen S, Liekens S, Sampaio AH, Nagano CS, Renata Costa Rocha C, Nascimento KS, Cavada BS, et al. 2019. Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity. *Medchemcomm.* 10:390–398.
- Gordts SC, Renders M, Ferir G, Huskens D, Van Damme EJ, Peumans W, Balzarini J, Schols D. 2015. NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles. *J Antimicrob Chemother.* 70:1674–1685.
- Greig AS, Bouillant AM. 1977. Binding effects of concanavalin A on a coronavirus. *Can J Comp Med.* 41:122–126.
- Guo Y, Yu H, Zhong Y, He Y, Qin X, Qin Y, Zhou Y, Zhang P, Zhang Y, Li Z, et al. 2018. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. *Medicine (Baltimore).* 97:e0208.
- Hamorsky KT, Kouokam JC, Dent MW, Grooms TN, Husk AS, Hume SD, Rogers KA, Villinger F, Morris MK, Hanson CV, et al. 2019. Engineering of a Lectibody targeting high-mannose-type glycans of the HIV envelope. *Mol Ther.* 27:2038–2052.
- Hargett AA, Renfrow MB. 2019. Glycosylation of viral surface proteins probed by mass spectrometry. *Curr Opin Virol.* 36:56–66.
- Hiono T, Matsuda A, Wagatsuma T, Okamatsu M, Sakoda Y, Kuno A. 2019. Lectin microarray analyses reveal host cell-specific glycan profiles of the hemagglutinins of influenza A viruses. *Virology.* 527:132–140.
- Hong SA, Kwon J, Kim D, Yang S. 2015. A rapid, sensitive and selective electrochemical biosensor with concanavalin A for the preemptive detection of norovirus. *Biosens Bioelectron.* 64:338–344.
- Hoorelbeke B, Huskens D, Ferir G, Francois KO, Takahashi A, Van Laethem K, Schols D, Tanaka H, Balzarini J. 2010. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. *Antimicrob Agents Chemother.* 54:3287–3301.
- Hopper JTS, Ambrose S, Grant OC, Krumm SA, Allison TM, Degiacomi MT, Tully MD, Pritchard LK, Ozorowski G, Ward AB, et al. 2017. The tetrameric plant lectin BanLec neutralizes HIV through bidentate binding to specific viral glycans. *Structure.* 25:773–782.e5.
- Hsieh LE, Lin CN, Su BL, Jan TR, Chen CM, Wang CH, Lin DS, Lin CT, Chueh LL. 2010. Synergistic antiviral effect of *Galanthus nivalis* agglutinin and nelfinavir against feline coronavirus. *Antivir Res.* 88:25–30.
- Hu B, Du T, Li C, Luo S, Liu Y, Huang X, Hu Q. 2015. Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-N and *Galanthus nivalis* agglutinin. *J Gen Virol.* 96:3660–3666.
- Huskens D, Ferir G, Vermeire K, Kehr JC, Balzarini J, Dittmann E, Schols D. 2010. Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from *Microcystis aeruginosa*, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. *J Biol Chem.* 285:24845–24854.
- Irvine EB, Alter G. 2020. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. *Glycobiology.* 30:241–253.
- Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. 2020. SARS-CoV-2 and ORF3a: Nonsynonymous mutations, functional domains, and viral pathogenesis. *mSystems.* 5:e00266–20.
- Jackson LA, Anderson EJ, Roupheal NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. 2020. An mRNA vaccine against SARS-CoV-2—Preliminary report. *N Engl J Med.*
- Jandu JJB, Neto RNM, Zagnignan A, de Sousa EM, Brelaz-de-Castro MCA, Dos Santos Correia MT, da Silva LCN. 2017. Targeting the immune system with plant lectins to combat microbial infections. *Front Pharmacol.* 8:671.
- Kachko A, Loesgen S, Shahzad-Ul-Hussan S, Tan W, Zubkova I, Takeda K, Wells F, Rubin S, Bewley CA, Major ME. 2013. Inhibition of hepatitis C virus by the cyanobacterial protein *Microcystis viridis* lectin: Mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. *Mol Pharm.* 10:4590–4602.
- Kaplan BS, Vincent AL. 2020. Detection and titration of influenza A virus neuraminidase inhibiting (NAI) antibodies using an enzyme-linked Lectin assay (ELLA). *Methods Mol Biol.* 2123:335–344.
- Keeffe JR, Gnanaprasam PN, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL. 2011. Designed oligomers of cyanovirin-N show enhanced HIV neutralization. *Proc Natl Acad Sci U S A.* 108:14079–14084.
- Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H, Balzarini J, Van Ranst M. 2007. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. *Antivir Res.* 75:179–187.
- Kim Y, Kim I, Park CH, Kim JB. 2018. Korean mistletoe lectin enhances natural killer cell cytotoxicity via upregulation of perforin expression. *Asian Pac J Allergy Immunol.* 36:175–183.
- Koch B, Schult-Dietrich P, Buttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H. 2018. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. *Blood Purif.* 46:126–133.
- Kumaki Y, Wandersee MK, Smith AJ, Zhou Y, Simmons G, Nelson NM, Bailey KW, Vest ZG, Li JK, Chan PK, et al. 2011. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, *Urtica dioica* agglutinin. *Antivir Res.* 90:22–32.
- Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. 2020. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). *Virus.* 31:13–21.
- Landi A, Mari M, Kleiser S, Wolf T, Gretzmeier C, Wilhelm I, Kiritsi D, Thunauer R, Geiger R, Nyström A, et al. 2019. Pseudomonas aeruginosa lectin LecB impairs keratinocyte fitness by abrogating growth factor signalling. *Life Sci Alliance.* 2.
- Lavelle EC, Grant G, Pusztai A, Pfuller U, Leavy O, McNeela E, Mills KH, O'Hagan DT. 2002. Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. *Immunology.* 107:268–274.
- Lee C. 2019. Griffithsin, a highly potent broad-spectrum antiviral lectin from red algae: From discovery to clinical application. *Mar Drugs.* 17:567.
- Lei Y, Chen W, Liang H, Wang Z, Chen J, Hong H, Xie L, Nie H, Xiong S. 2019. Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1. *Arch Virol.* 164:1259–1269.
- Li L, Yang R, Wang J, Lv Q, Ren M, Zhao L, Chen H, Xu H, Xie S, Xie J, et al. 2020b. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. *Transfusion.* 60:1773–1777.
- Li R, Tian J, Yang F, Lv L, Yu J, Sun G, Ma Y, Yang X, Ding J. 2020a. Clinical characteristics of 225 patients with COVID-19 in a tertiary hospital near Wuhan, China. *J Clin Virol.* 127:104363.
- Liang KH, Chang TJ, Wang ML, Tsai PH, Lin TH, Wang CT, Yang DM. 2020. Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2. *J Chin Med Assoc.* 83:701–703.
- Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. 2020a. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol.* 127:104370.
- Liu YM, Shahed-Al-Mahmud M, Chen X, Chen TH, Liao KS, Lo JM, Wu YM, Ho MC, Wu CY, Wong CH, et al. 2020b. A carbohydrate-binding protein from the edible Lablab beans effectively blocks the infections of influenza viruses and SARS-CoV-2. *Cell Rep.* 32:108016.
- Lo MK, Spengler JR, Krumpke LRH, Welch SR, Chattopadhyay A, Harmon JR, Coleman-McCray JD, Scholte FEM, Hotard AL, Fuqua JL, et al. 2020. Griffithsin inhibits Nipah virus entry and fusion and can protect Syrian golden hamsters from lethal Nipah virus challenge. *J Infect Dis.* 221:S480–S492.



- Luna DM, Oliveira MD, Nogueira ML, Andrade CA. 2014. Biosensor based on lectin and lipid membranes for detection of serum glycoproteins in infected patients with dengue. *Chem Phys Lipids*. 180:7–14.
- Ma LB, Xu BY, Huang M, He QG. 2018. Effects of recombinant *Agrocybe aegerita* lectin as an immunoadjuvant on immune responses. *Immunopharmacol Immunotoxicol*. 40:6–12.
- Ma LB, Xu BY, Huang M, Sun LH, Yang Q, Chen YJ, Yin YL, He QG, Sun H. 2017. Adjuvant effects mediated by the carbohydrate recognition domain of *Agrocybe aegerita* lectin interacting with avian influenza H9N2 viral surface glycosylated proteins. *J Zhejiang Univ Sci B*. 18:653–661.
- Major M, Law M. 2019. Detection of antibodies to HCV E1E2 by lectin-capture ELISA. *Methods Mol Biol*. 1911:421–432.
- Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M. 2020. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. *Virus Res*. 197989.
- Matei E, Zheng A, Furey W, Rose J, Aiken C, Gronenborn AM. 2010. Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization. *J Biol Chem*. 285:13057–13065.
- McFadden K, Cocklin S, Gopi H, Baxter S, Ajith S, Mahmood N, Shattock R, Chaiken I. 2007. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. *Proteins*. 67:617–629.
- Meagher JL, Winter HC, Ezell P, Goldstein IJ, Stuckey JA. 2005. Crystal structure of banana lectin reveals a novel second sugar binding site. *Glycobiology*. 15:1033–1042.
- Millet JK, Seron K, Labitt RN, Danneels A, Palmer KE, Whittaker GR, Dubuisson J, Belouzard S. 2016. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. *Antivir Res*. 133:1–8.
- Min YQ, Duan XC, Zhou YD, Kulnich A, Meng W, Cai ZP, Ma HY, Liu L, Zhang XL, Voglmeir J. 2017. Effects of microvirin monomers and oligomers on hepatitis C virus. *Biosci Rep*. 37.
- Mitchell CA, Ramessar K, O'Keefe BR. 2017. Antiviral lectins: Selective inhibitors of viral entry. *Antivir Res*. 142:37–54.
- Moulaei T, Alexandre KB, Shenoy SR, Meyerson JR, Krumpke LR, Constantine B, Wilson J, Buckheit RW Jr, McMahon JB, Subramaniam S, et al. 2015. Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus. *Retrovirology*. 12:6.
- Moulaei T, Shenoy SR, Giomarelli B, Thomas C, McMahon JB, Dauter Z, O'Keefe BR, Wlodawer A. 2010. Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. *Structure*. 18:1104–1115.
- Nguyen TD, Bottreau E, Aynaud JM. 1987. Influence of concanavalin a on the attachment of the coronavirus of transmissible gastroenteritis in cell cultures. *Ann Rech Vet*. 18:255–259.
- O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, et al. 2010. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. *J Virol*. 84:2511–2521.
- Ohyama Y, Nakajima K, Renfrow MB, Novak J, Takahashi K. 2020. Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins. *Expert Rev Proteomics*. 1–22.
- Oliveira Brito PKM, Goncalves TE, Fernandes FF, Miguel CB, Rodrigues WF, Lazo Chica JE, Roque-Barreira MC, da Silva TA. 2017. Systemic effects in naive mice injected with immunomodulatory lectin ArtinM. *PLoS One*. 12:e0187151.
- Oliveira MD, Correia MT, Diniz FB. 2009. Concanavalin a and polyvinyl butyral use as a potential dengue electrochemical biosensor. *Biosens Bioelectron*. 25:728–732.
- Oliveira MD, Nogueira ML, Correia MT, Coelho LC, Andrade CA. 2011. Detection of dengue virus serotypes on the surface of gold electrode based on *Cratylia mollis* lectin affinity. *Sensor Actuat B-Chem*. 155:789–795.
- Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun*. 11:1620.
- Parajuli B, Acharya K, Bach HC, Parajuli B, Zhang S, Smith AB 3rd, Abrams CF, Chaiken I. 2018. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus. *Biochem J*. 475:931–957.
- Parajuli B, Acharya K, Yu R, Ngo B, Rashad AA, Abrams CF, Chaiken IM. 2016. Lytic inactivation of human immunodeficiency virus by dual engagement of gp120 and gp41 domains in the virus Env protein Trimer. *Biochemistry*. 55:6100–6114.
- Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, et al. 2020. Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). *Open Forum Infect Dis*. 7:ofaa130.
- Patra D, Mishra P, Surolia A, Vijayan M. 2014. Structure, interactions and evolutionary implications of a domain-swapped lectin dimer from *Mycobacterium smegmatis*. *Glycobiology*. 24:956–965.
- Peeples L. 2020. News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. *Proc Natl Acad Sci U S A*. 117:8218–8221.
- Prado Acosta M, Lepenies B. 2019. Bacterial glycans and their interactions with lectins in the innate immune system. *Biochem Soc Trans*. 47:1569–1579.
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, et al. 2020. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. 71:762–768.
- Qin X, Guo Y, Du H, Zhong Y, Zhang J, Li X, Yu H, Zhang Z, Jia Z, Li Z. 2017. Comparative analysis for glycopatterns and complex-Type N-Glycans of glycoprotein in sera from chronic hepatitis B- and C-infected patients. *Front Physiol*. 8:596.
- Qin Y, Zhong Y, Ma T, Wu F, Wu H, Yu H, Huang C, Li Z. 2016. Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV. *Glycoconj J*. 33:125–136.
- Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. 2020. Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. *ACS Nano*.
- Requia WJ, Kondo EK, Adams MD, Gold DR, Struchiner CJ. 2020. Risk of the Brazilian health care system over 5572 municipalities to exceed health care capacity due to the 2019 novel coronavirus (COVID-19). *Sci Total Environ*. 730:139144.
- Reyna-Margarita HR, Irais CM, Mario-Alberto RG, Agustina RM, Luis-Benjamin SG, David PE. 2019. Plant phenolics and lectins as vaccine adjuvants. *Curr Pharm Biotechnol*. 20:1236–1243.
- Ribeiro AC, Monteiro SV, Carrapico BM, Ferreira RB. 2014. Are vicilins another major class of legume lectins? *Molecules*. 19:20350–20373.
- Ricci-Azevedo R, Roque-Barreira MC, Gay NJ. 2017. Targeting and recognition of toll-like receptors by plant and pathogen Lectins. *Front Immunol*. 8:1820.
- Rothan HA, Byrareddy SN. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun*. 109:102433.
- Ruterbusch M, Pruner KB, Shehata L, Pepper M. 2020. In vivo CD4(+) T cell differentiation and function: Revisiting the Th1/Th2 paradigm. *Annu Rev Immunol*. 38:705–725.
- Seber Kasinger LE, Dent MW, Mahajan G, Hamorsky KT, Matoba N. 2019. A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system. *Plant Biotechnol J*. 17:1646–1656.
- Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, Lee CS, Jun S, Park D, Kim HG, et al. 2020. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. *ACS Nano*. 14:5135–5142.
- Shah RR, Hassett KJ, Brito LA. 2017. Overview of vaccine adjuvants: Introduction, history, and current status. *Methods Mol Biol*. 1494:1–13.
- Shahid M, Qadir A, Yang J, Ahmad I, Zahid H, Mirza S, Windisch MP, Shahzad-Ul-Hussan S. 2020. An engineered microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry. *Viruses*. 12.
- Shahzad-ul-Hussan S, Gustchina E, Ghirlando R, Clore GM, Bewley CA. 2011. Solution structure of the monovalent lectin microvirin in complex with man(alpha)(1-2)man provides a basis for anti-HIV activity with low toxicity. *J Biol Chem*. 286:20788–20796.
- Shajahan A, Supekar NT, Gleinich AS, Azadi P. 2020. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. *Glycobiology*. cwaa042 (in press).

- Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. 2019. Vaccine adjuvants: Understanding the structure and mechanism of adjuvant activity. *Vaccine*. 37:3167–3178.
- Silva MLS. 2018. Lectin-based biosensors as analytical tools for clinical oncology. *Cancer Lett*. 436:63–74.
- Simao EP, Silva DBS, Cordeiro MT, Gil LHV, Andrade CAS, Oliveira MDL. 2020. Nanostructured impedimetric lectin-based biosensor for arboviruses detection. *Talanta*. 208:120338.
- Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, Mishin VP, Gubareva LV. 2008. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. *Antivir Res*. 80:266–271.
- Song SK, Moldoveanu Z, Nguyen HH, Kim EH, Choi KY, Kim JB, Mestecky J. 2007. Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice. *Vaccine*. 25:6359–6366.
- Sternberg A, Naujokat C. 2020. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. *Life Sci*. 257:118056.
- Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J, et al. 2020b. COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. *Trends Mol Med*. 26:483–495.
- Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X. 2020a. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clin Chim Acta*. 507:174–180.
- Swanson MD, Boudreaux DM, Salmon L, Chugh J, Winter HC, Meagher JL, Andre S, Murphy PV, Oscarson S, Roy R, et al. 2015. Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. *Cell*. 163:746–758.
- Swanson MD, Winter HC, Goldstein IJ, Markovitz DM. 2010. A lectin isolated from bananas is a potent inhibitor of HIV replication. *J Biol Chem*. 285:8646–8655.
- Thompson AJ, Cao L, Ma Y, Wang X, Diedrich JK, Kikuchi C, Willis S, Worth C, McBride R, Yates JR 3rd, et al. 2020. Human influenza virus Hemagglutinins contain conserved oligomannose N-linked glycans allowing potent neutralization by lectins. *Cell Host Microbe*. 27:725–735.
- Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V. 2009. Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients. *Blood Purif*. 27:64–69.
- Tullis RH, Duffin RP, Ichim TE, Joyce JA, Levin NW. 2010. Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis. *Blood Purif*. 29:210–215.
- Tung Y-T, Liang J-J, Feng H-T, Jhang R-N, Hsieh S-L, Lin Y-L, Wang G-J. 2019. Investigation of the extremely weak interaction between the Japanese encephalitis virus and CLEC5A using a multivalent-interaction-enhancement sensing electrode. *Biosens Bioelectron X*. 2:100024.
- Turgutkaya A, Yavasoglu I, Bolaman Z. 2020. The application of Plasmapheresis for Covid-19 patients. *Ther Apher Dial*.
- Tyo KM, Lasnik AB, Zhang L, Mahmoud M, Jenson AB, Fuqua JL, Palmer KE, Steinbach-Rankins JM. 2020. Sustained-release griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections. *J Control Release*. 321:84–99.
- Van Breedam W, Pohlmann S, Favoreel HW, de Groot RJ, Nauwynck HJ. 2014. Bitter-sweet symphony: Glycan-lectin interactions in virus biology. *FEMS Microbiol Rev*. 38:598–632.
- van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Peumans WJ, Van Damme EJ, Delpitte PL, Balzarini J, Egberink HF. 2007a. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. *Antivir Res*. 76:21–29.
- van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Verheije MH, Bosch BJ, Balzarini J, Egberink HF. 2007b. The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. *J Antimicrob Chemother*. 60:741–749.
- van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato V, Bushmaker T, Flaxman A, Ulaszewska M, et al. 2020. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in *Rhesus macaques*. *Nature*. 586:578–582.
- Vankadari N, Wilce JA. 2020. Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. *Emerg Microbes Infect*. 9:601–604.
- Vashi Y, Jagrit V, Kumar S. 2020. Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens. *Infect Genet Evol*. 84:104382.
- Venkatakrishnan K, Yalkinoglu O, Dong JQ, Benincosa LJ. 2020. Challenges in drug development posed by the COVID-19 pandemic: An opportunity for clinical pharmacology. *Clin Pharmacol Ther*. 108:699–702.
- Verma J, Subbarao N, Rajala MS. 2020. Envelope proteins as antiviral drug target. *J Drug Target*. 1–21.
- Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. 2018. Understanding modern-day vaccines: What you need to know. *Ann Med*. 50:110–120.
- Wagatsuma T, Kuno A, Angata K, Tajiri K, Takahashi J, Korenaga M, Mizokami M, Narimatsu H. 2018. Highly sensitive glycan profiling of hepatitis B viral particles and a simple method for dane particle enrichment. *Anal Chem*. 90:10196–10203.
- Walls AC, Park YJ, Tortorico MA, Wall A, McGuire AT, Veesele D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 181:281–292.e6.
- Wang D, Tang J, Tang J, Wang LX. 2015. Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: Progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins. *Molecules*. 20:4610–4622.
- Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. 2020. Site-specific glycan analysis of the SARS-CoV-2 spike. *Science*. 369:330–333.
- Watanabe Y, Bowden TA, Wilson IA, Crispin M. 2019. Exploitation of glycosylation in enveloped virus pathobiology. *Biochim Biophys Acta Gen Subj*. 1863:1480–1497.
- Woodrum BW, Maxwell J, Allen DM, Wilson J, Krumpke LR, Bobkov AA, Hill RB, Kibler KV, O'Keefe BR, Ghirlanda G. 2016. A designed “nested” dimer of cyanovirin-N increases antiviral activity. *Viruses*. 8:158.
- Wu C, Chen W, Chen J, Han B, Peng Z, Ge F, Wei B, Liu M, Zhang M, Qian C, et al. 2015. Preparation of monoPEGylated cyanovirin-N's derivative and its anti-influenza virus bioactivity in vitro and in vivo. *J Biochem*. 157:539–548.
- Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX, Miao Q. 2020. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. *J Infect*. 81:e51–e60.
- Yang H, Li J, Patel SK, Palmer KE, Devlin B, Rohan LC. 2019. Design of poly(lactide-co-glycolic acid) (PLGA) nanoparticles for vaginal co-delivery of griffithsin and dapivirine and their synergistic effect for HIV prophylaxis. *Pharmaceutics*. 11:184.
- Ye Q, Wang B, Mao J. 2020. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. *J Infect*. 80:607–613.
- Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, et al. 2019. Wisteria floribunda agglutinin-positive mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. *PLoS One*. 14:e0220663.
- Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. 2020. COVID-19: What has been learned and to be learned about the novel coronavirus disease. *Int J Biol Sci*. 16:1753–1766.
- Zappe H, Snell ME, Bossard MJ. 2008. PEGylation of cyanovirin-N, an entry inhibitor of HIV. *Adv Drug Deliv Rev*. 60:79–87.
- Zhang YZ, Holmes EC. 2020. A genomic perspective on the origin and emergence of SARS-CoV-2. *Cell*. 181:223–227.
- Zhou D, Tian X, Qi R, Peng C, Zhang W. 2020. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics. *Glycobiology*. cwaa052 (in press).
- Ziolkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A. 2006. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. *Structure*. 14:1127–1135.